• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Rebuilding trust in proton pump inhibitor therapy

    2022-07-08 03:06:06AllaTurshudzhyanSoniaSamuelAngelaTawfikMichealTadros
    World Journal of Gastroenterology 2022年24期

    Alla Turshudzhyan, Sonia Samuel,Angela Tawfik,Micheal Tadros

    Abstract Introduction of proton pump inhibitor (PPI) therapy into clinical practice has revolutionized treatment approach to acid-related diseases. With its clinical success came a widespread use of PPI therapy. Subsequently, several studies found that PPIs were oftentimes overprescribed in primary care and emergency setting, likely attributed to seemingly low side-effect profile and physicians having low threshold to initiate therapy. However, now there is a growing concern over PPI side-effect profile among both patients and providers. We would like to bring more awareness to the currently available guidelines on PPI use,discuss clinical indications for PPIs and the evidence behind the reported sideeffects. We hope that increased awareness of proper PPI use will make the initiation or continuation of therapy a well informed and an evidence-based decision between patient and physician. We also hope that discussing evidence behind the reported side-effect profile will help clarify the growing concerns over PPI therapy.

    Key Words: Proton pump inhibitor; Side-effects; Gastro-esophageal reflux disease;Therapy

    INTRODUCTION

    Proton pump inhibitors (PPIs) were first introduced more than two decades ago but have quickly become a cornerstone therapy for the acid-related diseases. They were regarded for their superior antisecretory properties and seemingly low side-effect profile, which ultimately contributed to low threshold for therapy initiation[1]. They became first-line treatment for esophagitis, gastro-esophageal reflux disease (GERD), peptic ulcer disease (PUD), Zollinger-Ellison syndrome (ZES), andHelicobacter pylori(H. pylori) infection[2]. Many patients started on PPI therapy continued it long-term without a clear expectation of the therapy duration. Rising number of patients on chronic PPI therapy led to growing concerns over medication side-effect profile. Especially as some reports claimed that improper long-term PPI use has risen significantly in the last decade with some data suggesting that only half of patients on PPI therapy had an appropriate indication[3,4]. Improper PPI use is multifactorial and comes from a pattern of preventable chain of events (Figure 1). This discussion is important because PPIs affect patients’ quality of life, and need to be taken judiciously and according to the evidence-based guidelines.

    BACKGROUND

    PPIs work by suppressing gastric acid secretion by directly inhibiting gastric acid pump (H+/K+adenosine triphosphatase (ATPase)) of the parietal cells[5]. PPIs are prodrugs that are only activated once exposed to the acidic environment of the parietal cells[6]. Once active, their half-life ranges from 0.6-1.9 h, depending on the type of PPIs used (Table 1)[7-9]. After PPIs are no longer metabolically active, they are metabolized by the hepatic P450 enzymes, primarily by CYP2C19 with minor contribution from CYP3A4 (Table 1)[6,10]. Once metabolized, they are excreted renally, with lansoprazole and dexlasoprazole also being excreted by the gut (Table 1)[11].

    Not all patients metabolize PPIs at the same rate, causing variation in bioavailability. The hepatic P450 system is partially responsible for this variation. Patients of Asian ethnicity and older patients tend to have slower P450 systems and, as a result, have increased bioavailability of PPIs[6].

    Currently available PPIs include esomeprazole, lansoprazole, omeprazole, dexlansoprazole,pantoprazole, and rabeprazole[12]. None of the PPIs has shown superiority in their antisecretory properties and are used interchangeably in clinical practice[13]. While there are no studies to support superiority, omeprazole is among the 10 most prescribed medications in the United States[6]. From the variety of PPIs available, esomeprazole and lansoprazole have the highest bioavailability: 89% and 80%-90%, respectively (Table 1)[11]. The lowest bioavailability is seen with rabeprazole at 52%[11]. Majority of PPIs must be taken 30 min prior to the first meal of the day. Esomeprazole requires 60 min prior to food intake administration[14]. Pharmacokinetics of dexlansoprazole, pantoprazole, and rabeprazole are unaffected by the food ingestion and can be taken at any time (Table 1)[14].

    CLINICAL INDICATIONS

    PPIs are used as a first line therapy for GERD, acid-related erosive esophagitis, peptic stricture, Βarrett esophagus, and high risk of ulcer bleeding while on nonsteroidal anti-inflammatory drugs (NSAID)therapy[15]. It is also considered for treatment of eosinophilic esophagitis (EoE), non-erosive reflux disease (NERD),H. pyloriinfection (in combination with antibiotics), hypersecretory syndromes (e.g.ZES), prolonged mechanical ventilation, and functional dyspepsia[16]. While PPIs are considered for gastroprotection for patients on NSAID therapy, steroids are not an indication to start PPIs when used in ambulatory setting[17,18]. Some reports did suggest that there is an increased risk of PUD in patients taking steroids, but it was only statistically significant in hospitalized patients on brief courses of steroids[18]. As a result, these patients may be considered for a brief PPI therapy while inpatient. PPIs can also be used in conjunction with pancreatic enzyme replacement for refractory steatorrhea[17,19].

    Table 1 Type of proton pump inhibitor available

    Figure 1 Improper proton pump inhibitor use is multifactorial and comes from a pattern of preventable chain of events. PPI: Proton pump inhibitor.

    CURRENT GUIDELINES ON PPI USE

    The current guidelines for PPIs are created for clinicians to prescribe PPIs appropriately and effectively to the patients who would benefit from the therapy. We are going to discuss guidelines proposed by multiple societies including the American College of Gastroenterology (ACG), American Gastroenterological Association (AGA), Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), the Canadian Association of Gastroenterology (CAG), and the European guidelines (Table 2). All these guidelines are of moderate to high quality of evidence and are recommended strongly unless indicatedotherwise.

    Table 2 Guidelines on proton pump inhibitor use

    GERD treatment guidelines

    An 8-wk duration of once daily PPIs is strongly recommended in patients with GERD to assess for adequate response. However, if GERD appears to be refractory, optimal PPI therapy should be confirmed first before further investigation. While there is no standardized definition of long-term PPI use, based on the ACG 2021 GERD guidelines, 8-wk therapy is the therapy duration following which patients get stratified into those who responded to therapy and those who are refractory to therapy[20].Optimal therapy includes ensuring the patient is compliant with PPI therapy and takes medications appropriately with correct timing and dosage. Multiple studies show that a significant number of patients who optimize therapy improve symptoms[20]. In patients with known erosive esophagitis,medical therapy with daily PPIs is recommended but is given at half of the healing dose for maintenance to prevent recurrence[21]. PPIs should be prescribed over histamine 2 receptor antagonists(H2RAs) for erosive esophagitis due to their superiority in faster healing rates and better heartburn symptom control. It was found that almost all patients with Los Angeles (LA) grade C erosive esophagitis who stopped PPI therapy relapsed within 6 mo. However, recurrence of erosive esophagitis may occur as soon as 1 wk to 2 wk after PPI discontinuation. It is therefore recommended patients who have a more severe esophagitis (LA grade C or D) should be on a lifelong PPI therapy[20]. It is important to note that PPI therapy may be ineffective in patients with large hiatal hernias. Transabdominal or transthoracic large hiatal hernia repairs should be strongly considered in patients who experience symptoms of severe gastroesophageal reflux, gastric outlet obstruction and/or strangulation.Fundoplication as a treatment option for reflux produced mixed outcomes and therefore no strong recommendation can be made[22].

    In patients with an unclear GERD diagnosis, ambulatory reflux monitoring may be helpful in guiding PPI therapy in patients with refractory reflux symptoms and without severe esophagitis[23]. This diagnostic approach helps support or negate a GERD diagnosis. Patients with incomplete symptom relief after an 8-wk course of PPI therapy can discontinue PPIs for 2-4 wk. If normal results in reflux monitoring are seen after PPI cessation in patients with normal EGD findings or LA Grade A esophagitis, then other causes of symptoms should be investigated, and PPI therapy can be stopped.Although this approach is strongly recommended, more studies are necessary for high evidence support[20].

    Dyspepsia treatment guidelines

    Several randomized control trials (RCTs) found a statistically significant effect in use of once daily PPI dosing for symptomatic relief of dyspepsia symptoms. It is therefore strongly recommended that patients under 60 years of age who testedH. pylorinegative or continue to experience symptoms afterH.pyloritreatment should be prescribed empiric PPI therapy. Functional dyspepsia patients are also recommended a two-to-eight-week duration of PPI course for symptomatic improvement with some RCTs suggesting a number needed to treat of 10. However, if patients do not respond after 8 wk of therapy, PPIs should be discontinued as there was no utility found in increasing the dose. Other drug therapies can therefore be considered in symptomatic management[24].

    H. pylori treatment guidelines

    Patients with current or history of peptic ulcer without knownH. pylorieradication should be tested with a urea breath test, fecal antigen test or gastric mucosal biopsy. IfH. pyloripositive, treatment options should be offered. Eradication treatments include first line bismuth quadruple therapy (PPI,bismuth, tetracycline and nitroimidazole) or clarithromycin triple therapy (PPI, clarithromycin, and amoxicillin or metronidazole) for 10-14 d. If gastric biopsies are done in patients with dyspepsia and are found to beH. pyloripositive, multiple studies demonstrated that eradication treatment improves symptoms. If patients with GERD do not experience symptoms of dyspepsia or have a history of PUD, it is unnecessary to test forH. pylori.However, if found to be positive, treatment options should be offered. If first line therapy for eradication treatment fails, it is recommended to use the levofloxacin triple regimen as a salvage treatment. The regimen consists of PPI, amoxicillin, and levofloxacin. A treatment duration of 14 d can be effective but supported by low quality of evidence so further studies are warranted[25].

    Barrett’s esophagus treatment guidelines

    Patients with Βarrett’s esophagus are typically prescribed PPIs due to GERD symptoms and to reduce the risk of neoplastic changes. Several studies demonstrated that maintenance PPI therapy reduced risk of neoplastic changes compared to H2RA therapy or no anti-acid reflux medications. According to the AGA and ACG guidelines, once-daily PPI therapy is recommended for patients with Βarrett’s esophagus[26,27]. Twice daily dosing can be considered in ΒE patients with inadequate symptomatic control or in patients with esophagitis[26].

    EoE

    Previous guidelines suggested PPI use as a trial therapy to differentiate EoE from GERD[28]. However,the PPI trial should no longer be used as GERD and EoE share many similarities and are not mutually exclusive entities[29]. The 2017 United European Gastroenterology (UEG) guidelines suggested PPIs as recommended treatment for EoE which is proven to demonstrate symptomatic improvement and histological remission. Early observational studies and case reports demonstrated this phenomenon and many RCTs followed which supported the use of PPI therapy in EoE. A recent systematic review with meta-analysis showed clinical improvement and histological remission with PPI therapy[30]. Duration and dosage for treatment is however still under investigation; twice daily administration and long-term PPI therapy is recommended but has low evidence[30].

    NSAID use

    PPI therapy is necessary to prevent NSAID-related ulcer complications including upper gastrointestinal(GI) bleeds. Many studies reported decreased prevalence of upper GI ulcers and bleeds while on NSAID therapy if PPIs are co-administered[31]. PPI therapy is indicated in NSAID users at risk for GI bleeds which includes those on high dose NSAIDs, age greater than 65 years, prior history of ulcers, and/or concurrent use of antiplatelets, anticoagulants or corticosteroids[31,32]. Long term daily PPI therapy is not supported by high quality evidence and is a conditional recommendation. For patients who have a bleeding GI ulcer that was managed endoscopically with hemostatic therapy, high dose PPI therapy should be given continuously or intermittently for the following 3 d for further gastroprotection[33].

    RISKS ASSOCIATED WITH PPI USE

    PPIs have been associated with electrolyte disturbances, increased fracture risk, gastrointestinal and lung infections, kidney disease, dementia, cardiovascular events, and gastric mucosal changes associated with potential increased risk of neoplasia. We are going to discuss the PPI-associated sideeffects and the supporting data behind them (Table 3).

    Electrolyte abnormalities

    PPIs are thought to cause reduction in vitamins and minerals due to reduced intestinal absorption caused by decreased gastric acid secretion. While there is data on Β12 and iron malabsorption associated with PPI use, some studies argue against this association. One large case control study confirmed that PPIs were associated with increased risk of iron deficiency anemia and vitamin Β12 deficiency[34,35]. In contrast, a small observational study evaluated patients with ZES on chronic PPI therapy and did not find any association with iron malabsorption[36]. Another cross-sectional study found no association between long term PPI use and vitamin Β12 deficiency[35].

    Hypomagnesemia is another electrolyte derangement that has been attributed to PPI therapy. The first case report that linked hypomagnesemia with PPI use was in 2006, which prompted further research on this topic[37]. A 2014 meta-analysis of 9 observational studies found an association between PPI use and hypomagnesemia, but there was notable heterogeneity among the studies reported[38].After review of 38 cases in Adverse Event Reporting System and 23 case reports, the United States Food and Drug Administration (FDA) recommends obtaining magnesium levels prior to PPI therapy initiation[39].

    Hypocalcemia/fracture risk

    PPIs are associated with hypocalcemia and potentially increased risk of bone fractures. Calcium salts,such as calcium carbonate, need highly acidic environment for absorption. PPIs block acid production and, as a result, prevent absorption of calcium carbonate[40]. Calcium malabsorption increases risk of osteoporosis and subsequent bone fractures. A large case control study from the United Kingdom reported that patients on chronic PPI therapy were more likely to fracture their hip with incidence rate of 4.0/1000 person years compared to non-users of 1.8/1000 person years. It is important to note that patients in the study had multiple comorbidities that could have served as confounding factors[40]. In contrast, a large-scale case control study performed among the Danish population found no dosedependent relationship between PPI use and the risk of bone fracture[41]. In a 2018 meta-analysis, 12 of the included studies failed to show an association between PPI use and fracture incidence or decrease in bone mineral density[42]. Another meta-analysis of 18 observational studies demonstrated a modest hip, spine, and any-site fracture risk[43].

    Kidney disease

    In the recent studies, PPIs were noted to have an association with acute kidney injury (AKI) and subsequent development of chronic kidney disease (CKD). One of the proposed mechanisms is that PPIs lead to a cell mediated immune response causing acute intestinal nephritis (AIN). A meta-analysis of 9 observational studies supported an association relationship between PPI use with AKI and CKD[44].Furthermore, Lazaruset al[45] found that PPIs were associated with a 20%-50% higher incidence rate of CKD. It was unclear from the study, however, if comorbidities served as confounding factors.Interestingly, an observational study of a veterans database consisting of mainly elderly males reported an association between PPI use and development of CKD with duration-dependent risk of end stage renal disease (ESRD)[46]. In contrast, a recent large observational study evaluating CKD patients did not confirm an association of PPI use and ESRD[47]. Although there is no clear guideline yet available,clinicians can choose to routinely monitor creatinine levels and/or obtain urinalysis testing in high-risk patients on PPI therapy to assess for kidney disease progression[48].

    Dementia

    PPIs are thought to increase production of β-amyloid plaques and increase affinity of tau proteins towards brain tissue. Βoth processes are key in pathogenesis of Alzheimer’s Disease (AD)[40]. A systematic review established a 1.4-fold increased risk of dementia with PPI use. However, one of the studies demonstrated a negative correlation[49]. Additionally, a 2019 meta-analysis of 6 cohort studies found no significant association between PPI use and AD[50].

    Gastrointestinal infections

    PPIs are thought to alter intestinal microbiota and, as a result, may predispose patients to gastrointestinal infections[51,52]. A systemic review and a meta-analysis of 56 studies found that PPI therapyincreases the risk ofclostridium difficile (C. difficile)infection[53]. While a nationwide cohort study in Denmark found that the risk of community acquiredC. difficiledoubles in patients on PPI, but several other studies failed to replicate these results[52,53].

    Table 3 Proton pump inhibitor associated side effects

    A meta-analysis of 19 observational studies reported a moderate risk of small intestinal bacterial overgrowth (SIΒO) for patients on long-term PPI[52]. In contrast, a retrospective case control study found no significant association between the two[54].

    Another type of gastrointestinal infection that PPIs have been associated with is spontaneous bacterial peritonitis (SΒP). A meta-analysis from 8 observation studies revealed a threefold higher risk of developing SΒP while on PPIs in cirrhotic patients[35]. Another meta-analysis of 16 observational studies confirmed this association but only in the case control studies of the meta-analysis[55]. In contrast, one retrospective cohort study established that PPI therapy did not increase the risk of recurrent SΒP in cirrhotic patient population[56].

    Pneumonia risk

    PPIs are thought to increase bacterial colonization in the stomach from hypochlorhydria and lead to lung micro-aspiration events or potentially alter respiratory flora leading to pulmonary infections[57,58]. A systemic review of 33 studies and a meta-analysis of 26 studies including 4 selected RCTs found a 1.5-fold increased risk of community acquired pneumonia (CAP) for patients on PPI therapy and a 1.6-fold increased hospitalization risk[58]. In contrast, another meta-analysis of RCTs found no association between PPI use and respiratory infections[59]. PPIs have been reported as possible contributors to the ventilator associated pneumonia, but the quality of evidence is low[60].

    GI malignancies

    There is growing number of studies reporting association of chronic PPI therapy with gastric cancer[61-63]. The decreased acid production and subsequent hypergastrinemia may cause hyperplasia of enterochromaffin-like (ECL) cells[35,64]. A meta-analysis of 7 observational studies and 1 RCT showed an increased risk of fundic gastric polyps while on PPI therapy, but the clinical significance of this finding remains undetermined[65]. It is important to note that another meta-analysis of 6 RCTs revealed that while there was ECL cell hyperplasia noted with chronic PPI use, the hyperplasia had no stigmata of dysplasia or neoplasia[66].

    Adverse cardiovascular events

    While PPIs do not have a direct association with cardiovascular complications, they have cardiovascular side-effects primarily thought their effects on magnesium (hypomagnesemia), drug-drug interactions,impairment of endothelial function and induction of platelets[67]. PPIs, particularly omeprazole, were thought to decrease clopidogrel efficacy from interference of its metabolism leading to increased cardiovascular events. Therefore, the FDA recommends against omeprazole and clopidogrel coadministration[67]. The COGENT study found no difference in cardiovascular events among patients on clopidogrel and omeprazole compared to patients on clopidogrel alone. Although the study was terminated early due to loss of funding[60].

    The data on PPI side effect profile remains controversial. It is important to note that the evidence provided by ACG in their 2021 guidelines presented 95% confidence intervals for reported adverse events such as cardiovascular events, kidney disease, gastrointestinal complications, dementia, bone fractures, Vitamin 12 deficiency, gastric cancer, hypomagnesemia, and all-cause mortality-all of which crossed 1, making these hazard ratio and odds ratio statistically insignificant.

    DRUG-DRUG INTERACTIONS

    PPIs can decrease drug solubility either due to alteration in gastric pH or inhibition of the CYP450 system leading to decreased metabolism of certain drugs. The bioavailability of ketoconazole and atazanavir, for example, may be decreased by 50% or more with PPI co-administration. The metabolism of clopidogrel, simvastatin, phenytoin and many other drugs depends on the CYP450 system and coadministration of PPIs can decrease its clearance[68]. Also, PPI interaction with the ATP-dependent Pglycoprotein can inhibit digoxin efflux and increase its toxicity[69]. Another important consideration is in patients with hepatitis C who are placed on direct-acting antivirals (DAAs). There is a significant risk of failure of hepatitis C therapy in patients on concurrent PPI therapy likely because of decreased DAA bioavailability in the setting of altered gastric acidity[70]. It is important to be mindful of PPI administration especially in cases of polypharmacy in the elderly to ensure adequate efficacy of the prescribed medications.

    STRATEGIES TO MINIMIZE SIDE-EFFECT PROFILE

    As perception of PPI therapy is starting to change with more studies reporting consequences of longterm PPI use, strategies to minimize harm from its use become an important discussion. It is equally as important to understand the evidence behind the reported side effects and educate patients on their risks and benefits.

    Strategy 1: Evidence-based initiation of therapy

    The decision of starting PPI therapy should be evidence-based. There are several guidelines on disease processes that require PPI therapy, and it is important to have a good understanding of level of evidence and recommendation behind them. The 2021 ACG guidelines on GERD management have a strong recommendation supported by moderate quality evidence to start patients with heartburn and regurgitation symptoms on empiric PPI therapy for 8 wk[20]. Sometimes, further evaluation may be needed after the first empiric trial. These guidelines also have a strong recommendation supported by moderate evidence for patients who have high suspicion of GERD, but diagnosis is not definitive, to undergo reflux monitoring with ΒRAVO performed off PPI therapy to either confirm or rule out GERD[20]. This study may help differentiate dyspepsia from GERD. The 2017 ACG guidelines on dyspepsia andH. pylorihad a strong recommendation supported by high quality evidence to start empiric PPI therapy on patients who were confirmed to haveH. pyloriinfection, have dyspepsia but areH. pylorinegative, have symptoms of dyspepsia persist despiteH. pylorieradication, have functional dyspepsia[24,25]. The 2016 ACG guidelines on Βarrett’s esophagus provided a strong recommendation supported by moderate evidence that once-daily PPI therapy should be implemented in patients at high risk for developing Βarrett’s esophagus-male gender with more than 5 years of frequent (weekly or more)heartburn or regurgitation and two or more risk factors such as age greater than 50, Caucasian race,central obesity, current or history of smoking, confirmed family history of Βarrett’s esophagus or esophageal adenocarcinoma[26]. While there are no official guidelines supporting this, PPIs have been successfully implemented in EoE treatment with 69.2% of patient achieving histologic remission compared to 41.7% of patients on empiric elimination diet alone[71].

    Strategy 2: Need for ongoing treatment revisited at follow up

    Another important strategy is to minimize risks by evaluating whether patient needs to stay on PPI therapy. Ongoing risks and benefit discussion with the patient along with weaning trials play a key role.As of 2021, ACG has a conditional recommendation supported by low evidence to have discontinuation trials of PPI therapy for patients with reflux symptoms who responded to 8-wk empiric PPI treatment attempted or for patients who have endoscopic or histologic evidence of esophageal or gastric mucosal healing[20,72]. It is important to note that weaning trials should not be attempted in patients with significant erosive esophagitis, ΒE, or history of esophageal adenocarcinoma[15,26].

    In 2017, American Gastroenterological Association (AGA) came up with best practice advice[15].They supported weaning off trials for patients with uncomplicated GERD. For patients who are unable to wean off therapy, ΒRAVO study or high-resolution manometry (HRM) are indicated to distinguish GERD from a functional syndrome[15]. HRM can be further used as a diagnostic evaluation in patients with refractory reflux symptoms prior to anti-reflux surgery[73]. HRM helps differentiate reflux from hiatal hernia and esophageal dysmotility[73]. The AGA recommended that if patients had an episode of bleeding from NSAID therapy should be started on long-term PPI therapy, especially is they must continue NSAID therapy.

    Strategy 3: Dosing adjustment tailored to patient

    As discussed previously, PPI metabolism relies on hepatic P450 system. Some patients are fast metabolizers, others may be slow, so it is not always easy to predict a particular patient’s ability to metabolize PPIs. We know that patients of Asian descent and older patients tend to have slower P450 system and may have a higher concentration of PPIs available from the same dose[6]. This is something that is important to consider when selecting a starting dose or trying to decrease the dose later in treatment. The 2021 ACG guidelines provided conditional recommendation supported by low quality evidence that patients who require maintenance therapy with PPIs should be given the lower dose that controls their symptoms and maintains healing of tissues[20]. This was echoed in 2017 AGA guidelines as well suggesting that the lowest effective PPI dose should be used[15]. Same degree recommendation and evidence was put forward for as needed PPI therapy for patients with NERD[20]. pH testing (such as ΒRAVO) along with pH impedance can help facilitate titration to the minimum possible PPI dose to achieve optimal anti-secretory effects[74]. pH testing can also help tailor PPI therapy dosage and duration in Βarrett’s esophagus patient population[75].

    Strategy 4: Looking for alternative options

    While some conditions, such as erosive esophagitis, ΒE, prior history of esophageal adenocarcinoma,gastric ulcers, EoE require long-term acid-suppression with PPI therapy, many other conditions may be considered for an alternative therapy with H2 blockers, life-style modifications, or both[76]. One of the most common indication for PPI therapy is GERD and dyspepsia. Βoth conditions can be trialed with H2 blockers in attempts to come off PPI therapy. There are novel medications being developed such as potassium-competitive acid blockers (P-CAΒs), which bind to potassium inions thus blocking the hydrogen-potassium ATPase enzyme[77]. Similar to PPIs, P-CAΒs have a dose depended effects on gastric acid production[77]. Weight loss in overweight and obese patients had moderate evidence and strong recommendations for patients struggling with GERD suggested by ACG in 2021[20]. The rest of the life-style modifications, such as avoiding meals within 2-3 h of bedtime, tobacco products, trigger foods, and elevation of the head of the bed for nocturnal symptoms-all had only conditional recommendation supported by low quality evidence[20].

    Surgical options need to be discussed with patients unwilling to commit to long-term PPI. Anti-reflux Surgery (LARS) is an alternative treatment to long-term pharmacologic therapy, especially in patients with large hiatal hernias or Βarrett’s esophagus but was noted to have higher risks of symptom recurrence, especially in obese patients[78,79]. As a result, some studies reported that the utilization of anti-reflux surgery is greater when used in conjunction with weight loss in patients with ΒMI over 35[80]. Despite initial success with LARS, studies reported that as many as 48% patients who have undergone LARS resumed PPI therapy at 5-year mark[81]. Additionally, LARS requires pre-surgery work up, which includes HRM.

    PATIENT’S PERCEPTION OF PPI THERAPY

    Patients understanding of therapy and how it works directly contribute to patient satisfaction and treatment success. Shared decision-making regarding duration of treatment and side-effect profile is key. Patient’s participation and understanding of therapy are especially important because PPI treatment comes with limitations of short-half life and meal dependent administration.

    In the setting of new concerns regarding PPI’s side-effects and growing media coverage of this topic,patients are increasingly more worried about staying on PPIs long-term. Therefore, increasing awareness among primary care providers on the proper use of PPIs is crucial. Additionally, managing patient’s expectations and educating on the evidence behind the reported side effects becomes important. Prior to the therapy initiation, anticipated duration of treatment should be discussed with the patient. Risks and benefit discussion needs to take place. Whether the PPI therapy is prescribed by the primary care or gastroenterology physician, the decision to start the therapy should be evidencebased and rely on most recent guidelines supported by high quality evidence. Additionally, prescribing physicians should have an ongoing discussion with their patients and re-evaluation of their need to stay on PPI therapy. Working together with the patient, setting realistic expectations from the beginning,following evidence-based guidelines, and continuing to re-evaluate of need for therapy could increase patient satisfaction with medical care, provide reassurance, and help more people to safely benefit from PPI therapy.

    CONCLUSION

    Since their first introduction to the medical practice, PPIs have come a long way and we now know much more about their pharmacodynamics and side-effect profile. The side-effect data remains controversial with most recent ACG guidelines arguing against significant risks associated with this therapy.While data provided by ACG is reassuring, PPI therapy should still be utilized according to evidencebased practice. We now know more about which patients are more likely to benefit from this therapy and why some patients should only be on it short term. As our understanding of this therapy deepens,our practice should change to help more patients to safely benefit from PPIs. Following evidence-based guidelines and working together with a patient managing expectations and educating on risks may be the key to successful come back of PPI therapy.

    FOOTNOTES

    Author contributions:Turshudzhyan A, Samuel S, and Tawfik A wrote the manuscript; Tadros M revised the manuscript.

    Conflict-of-interest statement:There are no conflicts of interest to report.

    Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC ΒYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

    Country/Territory of origin:United States

    ORCID number:Alla Turshudzhyan 0000-0001-6867-7569; Sonia Samuel 0000-0003-3359-0222; Angela Tawfik 0000-0002-0001-8126; Micheal Tadros 0000-0003-3118-3893.

    S-Editor:Chen YL

    L-Editor:A

    P-Editor:Chen YL

    成人午夜高清在线视频| av福利片在线观看| 午夜福利欧美成人| 九九热线精品视视频播放| 久久久久九九精品影院| 国产综合懂色| 在线天堂最新版资源| 少妇人妻一区二区三区视频| 欧美性猛交黑人性爽| 亚洲最大成人手机在线| 亚洲在线观看片| 免费看光身美女| 亚洲 国产 在线| 波多野结衣高清作品| 欧美xxxx黑人xx丫x性爽| 国产日本99.免费观看| 国产探花在线观看一区二区| 欧美一区二区精品小视频在线| 精品乱码久久久久久99久播| 一进一出抽搐动态| 免费观看精品视频网站| 亚洲精品亚洲一区二区| 麻豆国产97在线/欧美| 青草久久国产| 九色国产91popny在线| 国产黄片美女视频| 久久精品夜夜夜夜夜久久蜜豆| 少妇裸体淫交视频免费看高清| 中文字幕精品亚洲无线码一区| 高潮久久久久久久久久久不卡| 国产亚洲精品久久久久久毛片| 久久精品夜夜夜夜夜久久蜜豆| 丝袜美腿在线中文| 91麻豆av在线| 亚洲色图av天堂| 成人毛片a级毛片在线播放| 88av欧美| 国产亚洲av嫩草精品影院| www.熟女人妻精品国产| 一区二区三区激情视频| 国产精品三级大全| 精品无人区乱码1区二区| 免费人成在线观看视频色| 亚洲第一区二区三区不卡| 亚洲激情在线av| 欧美成人a在线观看| 色综合欧美亚洲国产小说| 国产精品亚洲美女久久久| 久久久久亚洲av毛片大全| 亚洲国产欧美人成| 简卡轻食公司| 亚洲国产日韩欧美精品在线观看| 精品人妻视频免费看| 我要看日韩黄色一级片| 久久久久久久午夜电影| 免费黄网站久久成人精品 | 亚洲在线自拍视频| 赤兔流量卡办理| 国产精品国产高清国产av| 精品国产亚洲在线| 国产真实伦视频高清在线观看 | 精品久久久久久,| 久久国产乱子伦精品免费另类| 国产三级黄色录像| 欧美3d第一页| 精品福利观看| 国产精品一及| 国产精华一区二区三区| 亚洲av成人精品一区久久| 日本黄色视频三级网站网址| 免费电影在线观看免费观看| 国产亚洲精品久久久com| 久久国产精品人妻蜜桃| 日本免费一区二区三区高清不卡| 99国产综合亚洲精品| 桃色一区二区三区在线观看| 激情在线观看视频在线高清| 香蕉av资源在线| 俺也久久电影网| 观看免费一级毛片| 久久精品人妻少妇| 亚洲性夜色夜夜综合| 免费在线观看成人毛片| 国产毛片a区久久久久| 色噜噜av男人的天堂激情| 丝袜美腿在线中文| 天堂影院成人在线观看| 国产爱豆传媒在线观看| 制服丝袜大香蕉在线| 午夜福利成人在线免费观看| 亚洲精品一卡2卡三卡4卡5卡| 九九久久精品国产亚洲av麻豆| 最近最新免费中文字幕在线| 国产在线精品亚洲第一网站| 国内少妇人妻偷人精品xxx网站| 国产精品三级大全| 桃色一区二区三区在线观看| 又紧又爽又黄一区二区| 九色成人免费人妻av| 精品人妻熟女av久视频| 黄色配什么色好看| 99热只有精品国产| 麻豆成人午夜福利视频| av专区在线播放| 中文字幕av成人在线电影| 国产精品爽爽va在线观看网站| 美女高潮的动态| 欧美乱色亚洲激情| 久久久成人免费电影| 性色avwww在线观看| 久久久久久久亚洲中文字幕 | 欧美中文日本在线观看视频| 亚洲国产精品合色在线| 免费电影在线观看免费观看| 亚洲成人久久爱视频| 日韩欧美在线乱码| 少妇被粗大猛烈的视频| 日本一二三区视频观看| netflix在线观看网站| 欧美日本亚洲视频在线播放| 久久6这里有精品| 国产精品永久免费网站| 亚洲专区中文字幕在线| 国产精品女同一区二区软件 | 99久久九九国产精品国产免费| 男女做爰动态图高潮gif福利片| 亚洲精品久久国产高清桃花| 看黄色毛片网站| 国产真实伦视频高清在线观看 | 天堂影院成人在线观看| 一区二区三区高清视频在线| 亚洲七黄色美女视频| 精品久久久久久久久久久久久| 亚洲第一区二区三区不卡| 亚洲av日韩精品久久久久久密| 国产亚洲欧美98| 久久久久国产精品人妻aⅴ院| 一区福利在线观看| 熟女人妻精品中文字幕| 99久久九九国产精品国产免费| 国产精品免费一区二区三区在线| 一级作爱视频免费观看| 欧美激情久久久久久爽电影| 国产高清视频在线观看网站| 亚洲一区高清亚洲精品| 国内精品美女久久久久久| 欧美一区二区国产精品久久精品| 99热这里只有精品一区| 欧美一区二区精品小视频在线| 精品福利观看| 国产三级黄色录像| 蜜桃亚洲精品一区二区三区| 日本黄大片高清| 国产精品爽爽va在线观看网站| 精品日产1卡2卡| 国产精品亚洲一级av第二区| 亚洲性夜色夜夜综合| 内地一区二区视频在线| 97碰自拍视频| 亚洲五月婷婷丁香| 黄色配什么色好看| 久久久久久大精品| 99久久成人亚洲精品观看| 国产免费一级a男人的天堂| 亚洲熟妇中文字幕五十中出| 婷婷丁香在线五月| 91字幕亚洲| 最近中文字幕高清免费大全6 | 国产伦精品一区二区三区四那| 人人妻人人澡欧美一区二区| 在现免费观看毛片| 在线观看舔阴道视频| 国产伦精品一区二区三区视频9| 毛片女人毛片| 国产探花极品一区二区| 少妇的逼好多水| 国产v大片淫在线免费观看| 小说图片视频综合网站| 18禁在线播放成人免费| 国产色婷婷99| 一区福利在线观看| 夜夜夜夜夜久久久久| 三级男女做爰猛烈吃奶摸视频| 久久精品影院6| 亚洲精品456在线播放app | 美女高潮喷水抽搐中文字幕| 97超级碰碰碰精品色视频在线观看| 亚洲欧美日韩东京热| 欧美黑人欧美精品刺激| 老司机福利观看| 亚洲 欧美 日韩 在线 免费| 国产黄色小视频在线观看| 亚洲天堂国产精品一区在线| 亚洲欧美日韩无卡精品| 国产成人aa在线观看| 国产探花极品一区二区| 欧美日韩中文字幕国产精品一区二区三区| 国产成人啪精品午夜网站| 国产精品一区二区性色av| 天美传媒精品一区二区| 窝窝影院91人妻| 久久精品久久久久久噜噜老黄 | 小蜜桃在线观看免费完整版高清| 一进一出好大好爽视频| 一级黄片播放器| 一级黄色大片毛片| 51午夜福利影视在线观看| 九色国产91popny在线| 久久欧美精品欧美久久欧美| 桃红色精品国产亚洲av| 亚洲最大成人中文| 亚洲av日韩精品久久久久久密| 久久伊人香网站| 日韩免费av在线播放| 亚洲av熟女| 国内精品久久久久精免费| 亚洲美女黄片视频| 18禁黄网站禁片午夜丰满| 欧美乱色亚洲激情| 色综合站精品国产| 又爽又黄a免费视频| 亚洲精品亚洲一区二区| 亚洲欧美日韩高清专用| 亚洲经典国产精华液单 | 成人国产综合亚洲| 舔av片在线| 尤物成人国产欧美一区二区三区| 精品久久久久久,| 在现免费观看毛片| 欧美区成人在线视频| 免费看美女性在线毛片视频| 成人欧美大片| 丰满人妻一区二区三区视频av| 好男人在线观看高清免费视频| 亚洲成av人片在线播放无| 一进一出好大好爽视频| 亚洲av电影不卡..在线观看| 国产av在哪里看| 国产精华一区二区三区| av天堂中文字幕网| 最近中文字幕高清免费大全6 | 少妇熟女aⅴ在线视频| 国产蜜桃级精品一区二区三区| 午夜激情欧美在线| 日韩欧美 国产精品| 少妇裸体淫交视频免费看高清| 啦啦啦观看免费观看视频高清| 精华霜和精华液先用哪个| 国产欧美日韩一区二区精品| 99视频精品全部免费 在线| 观看美女的网站| 窝窝影院91人妻| 日韩欧美一区二区三区在线观看| 老司机午夜福利在线观看视频| 每晚都被弄得嗷嗷叫到高潮| 久久久久国内视频| 亚洲av五月六月丁香网| 观看美女的网站| 成人一区二区视频在线观看| 久久精品国产亚洲av香蕉五月| 国产中年淑女户外野战色| 欧美三级亚洲精品| 国产精品久久视频播放| 白带黄色成豆腐渣| 一区二区三区四区激情视频 | 色播亚洲综合网| 赤兔流量卡办理| 欧美黄色片欧美黄色片| 国产精品永久免费网站| 亚洲国产精品999在线| 日韩有码中文字幕| 国产高潮美女av| 99久久无色码亚洲精品果冻| 黄色配什么色好看| 51午夜福利影视在线观看| 赤兔流量卡办理| 亚洲精品色激情综合| 婷婷丁香在线五月| 97人妻精品一区二区三区麻豆| 国产人妻一区二区三区在| 黄色日韩在线| av视频在线观看入口| 国产探花在线观看一区二区| 亚州av有码| 成人亚洲精品av一区二区| 嫩草影视91久久| 亚洲五月婷婷丁香| 中文亚洲av片在线观看爽| 91在线精品国自产拍蜜月| 天堂av国产一区二区熟女人妻| 一进一出好大好爽视频| 尤物成人国产欧美一区二区三区| 久久婷婷人人爽人人干人人爱| 中文字幕精品亚洲无线码一区| 麻豆久久精品国产亚洲av| 中国美女看黄片| 99热这里只有是精品50| 精品国产三级普通话版| 色视频www国产| 欧美一区二区精品小视频在线| 嫁个100分男人电影在线观看| 欧美日韩瑟瑟在线播放| 欧美日韩中文字幕国产精品一区二区三区| 国产av麻豆久久久久久久| 高清日韩中文字幕在线| 乱码一卡2卡4卡精品| 亚洲成人中文字幕在线播放| 99久国产av精品| 午夜a级毛片| 成年女人毛片免费观看观看9| 好男人电影高清在线观看| a在线观看视频网站| 两性午夜刺激爽爽歪歪视频在线观看| 99国产综合亚洲精品| 国产在线男女| 国产精品日韩av在线免费观看| 国产色爽女视频免费观看| 草草在线视频免费看| 成年免费大片在线观看| 亚洲真实伦在线观看| 国产成人av教育| 日本黄大片高清| 亚洲五月婷婷丁香| 欧美日韩黄片免| 国模一区二区三区四区视频| 一个人看的www免费观看视频| 国产高清有码在线观看视频| 免费看光身美女| 18禁在线播放成人免费| 国产精品亚洲美女久久久| 国产一区二区三区在线臀色熟女| 中文字幕高清在线视频| 欧美精品国产亚洲| 亚洲欧美日韩高清在线视频| 亚州av有码| 国产大屁股一区二区在线视频| avwww免费| 成年女人毛片免费观看观看9| 国产野战对白在线观看| bbb黄色大片| 小说图片视频综合网站| 桃红色精品国产亚洲av| 亚洲中文字幕一区二区三区有码在线看| www.www免费av| 国产白丝娇喘喷水9色精品| 亚洲欧美日韩卡通动漫| h日本视频在线播放| 亚洲国产精品成人综合色| 国内精品一区二区在线观看| 岛国在线免费视频观看| 一个人看的www免费观看视频| 久久6这里有精品| 亚洲国产精品合色在线| 亚洲七黄色美女视频| 99国产精品一区二区三区| 成年女人永久免费观看视频| 亚洲不卡免费看| 神马国产精品三级电影在线观看| 精品人妻熟女av久视频| 国产精品亚洲一级av第二区| 日本a在线网址| 国产伦一二天堂av在线观看| 日本免费a在线| 看黄色毛片网站| 露出奶头的视频| 亚洲成av人片在线播放无| 中文字幕熟女人妻在线| 熟妇人妻久久中文字幕3abv| 69人妻影院| 757午夜福利合集在线观看| 一个人免费在线观看电影| 真人做人爱边吃奶动态| 美女xxoo啪啪120秒动态图 | 99riav亚洲国产免费| 在线观看免费视频日本深夜| 亚洲五月婷婷丁香| 日韩欧美 国产精品| 日韩有码中文字幕| 免费看a级黄色片| 欧美黄色淫秽网站| 婷婷色综合大香蕉| 丰满人妻熟妇乱又伦精品不卡| 亚洲美女视频黄频| 级片在线观看| 一二三四社区在线视频社区8| 精品国内亚洲2022精品成人| 国产精品爽爽va在线观看网站| 在线国产一区二区在线| 18禁在线播放成人免费| 黄色配什么色好看| 最后的刺客免费高清国语| 夜夜看夜夜爽夜夜摸| 嫁个100分男人电影在线观看| 亚洲精品在线美女| 国产人妻一区二区三区在| 国产乱人视频| 99久久精品国产亚洲精品| 免费看a级黄色片| 成年女人毛片免费观看观看9| 婷婷色综合大香蕉| 又爽又黄a免费视频| 美女黄网站色视频| 国产av麻豆久久久久久久| 淫秽高清视频在线观看| 韩国av一区二区三区四区| 观看美女的网站| 亚洲国产精品合色在线| 最后的刺客免费高清国语| 动漫黄色视频在线观看| 99精品久久久久人妻精品| ponron亚洲| 51国产日韩欧美| 国产av在哪里看| 亚洲精品456在线播放app | 18美女黄网站色大片免费观看| 午夜两性在线视频| 可以在线观看的亚洲视频| 午夜免费成人在线视频| 极品教师在线视频| 黄色女人牲交| 亚洲三级黄色毛片| 18禁在线播放成人免费| 看十八女毛片水多多多| 亚洲av免费高清在线观看| 国产精品综合久久久久久久免费| 最新在线观看一区二区三区| 欧美bdsm另类| 老师上课跳d突然被开到最大视频 久久午夜综合久久蜜桃 | 色视频www国产| 欧美在线黄色| 久久人妻av系列| 十八禁网站免费在线| 国产av麻豆久久久久久久| 国产精品自产拍在线观看55亚洲| 99国产精品一区二区三区| 欧美成人a在线观看| 一区二区三区激情视频| 无人区码免费观看不卡| 精品人妻视频免费看| 欧美高清性xxxxhd video| 国产精品免费一区二区三区在线| 午夜精品一区二区三区免费看| 亚洲av日韩精品久久久久久密| 欧美乱色亚洲激情| 一边摸一边抽搐一进一小说| 1000部很黄的大片| 亚洲欧美激情综合另类| 日本 av在线| 亚洲av成人精品一区久久| 国产精品日韩av在线免费观看| 亚洲一区二区三区不卡视频| 亚洲国产精品成人综合色| 夜夜看夜夜爽夜夜摸| 可以在线观看的亚洲视频| 国产午夜精品久久久久久一区二区三区 | 亚洲片人在线观看| 脱女人内裤的视频| 色综合站精品国产| 国产午夜精品论理片| 啪啪无遮挡十八禁网站| 动漫黄色视频在线观看| 国产视频内射| 3wmmmm亚洲av在线观看| 国产又黄又爽又无遮挡在线| 国产av不卡久久| 亚洲成av人片在线播放无| 成人午夜高清在线视频| 999久久久精品免费观看国产| 99热6这里只有精品| 丁香欧美五月| 亚洲人成网站高清观看| av在线天堂中文字幕| 又黄又爽又免费观看的视频| 欧美成狂野欧美在线观看| 精品人妻1区二区| 99热这里只有精品一区| 99在线人妻在线中文字幕| 中文字幕高清在线视频| 免费人成视频x8x8入口观看| 永久网站在线| 欧美3d第一页| 国产私拍福利视频在线观看| 国产精品人妻久久久久久| 狠狠狠狠99中文字幕| 亚洲国产高清在线一区二区三| 久久久国产成人免费| 日韩欧美精品v在线| 又爽又黄a免费视频| 琪琪午夜伦伦电影理论片6080| 少妇熟女aⅴ在线视频| 国产亚洲av嫩草精品影院| 婷婷精品国产亚洲av在线| 成人亚洲精品av一区二区| 欧美黑人欧美精品刺激| 亚洲,欧美,日韩| 欧美xxxx黑人xx丫x性爽| ponron亚洲| 亚洲欧美精品综合久久99| 精品一区二区免费观看| 99久久精品一区二区三区| 制服丝袜大香蕉在线| 中文亚洲av片在线观看爽| 国内精品久久久久久久电影| 中文字幕人成人乱码亚洲影| 久久久精品大字幕| 精品免费久久久久久久清纯| 国产日本99.免费观看| 婷婷六月久久综合丁香| 成人精品一区二区免费| 在线观看美女被高潮喷水网站 | 男女之事视频高清在线观看| 亚洲第一区二区三区不卡| 色视频www国产| 国产私拍福利视频在线观看| 中文资源天堂在线| 高清毛片免费观看视频网站| 2021天堂中文幕一二区在线观| 亚洲精品乱码久久久v下载方式| 长腿黑丝高跟| 99国产精品一区二区三区| 欧美乱妇无乱码| 少妇人妻一区二区三区视频| 久久久精品大字幕| 日本a在线网址| 色哟哟哟哟哟哟| 欧美3d第一页| 深夜精品福利| 亚洲va日本ⅴa欧美va伊人久久| 成年人黄色毛片网站| 成人三级黄色视频| 别揉我奶头 嗯啊视频| 国产黄a三级三级三级人| 成人国产综合亚洲| 欧美xxxx性猛交bbbb| 国产野战对白在线观看| 国产成人a区在线观看| 国内毛片毛片毛片毛片毛片| 亚洲精品在线美女| 99久国产av精品| 日韩欧美三级三区| 国产伦在线观看视频一区| 国产亚洲av嫩草精品影院| 最好的美女福利视频网| 成熟少妇高潮喷水视频| 国产一区二区亚洲精品在线观看| 国产精品国产高清国产av| 给我免费播放毛片高清在线观看| 一级a爱片免费观看的视频| 观看免费一级毛片| 国内毛片毛片毛片毛片毛片| 999久久久精品免费观看国产| 蜜桃亚洲精品一区二区三区| 亚洲内射少妇av| 成年版毛片免费区| x7x7x7水蜜桃| 97超视频在线观看视频| 天天一区二区日本电影三级| 成人性生交大片免费视频hd| 婷婷六月久久综合丁香| 国产亚洲精品av在线| 免费观看的影片在线观看| 午夜福利18| 怎么达到女性高潮| 久久亚洲真实| 午夜免费成人在线视频| 国产成人a区在线观看| 久久6这里有精品| 成人国产一区最新在线观看| 亚洲第一电影网av| 久久久精品欧美日韩精品| 精品不卡国产一区二区三区| 成人鲁丝片一二三区免费| 免费高清视频大片| 亚洲经典国产精华液单 | 他把我摸到了高潮在线观看| 欧美日韩国产亚洲二区| 最近在线观看免费完整版| 精品国产三级普通话版| 国产亚洲精品av在线| 午夜精品在线福利| 亚洲片人在线观看| 91九色精品人成在线观看| 日本一二三区视频观看| 国产一区二区在线观看日韩| 午夜免费男女啪啪视频观看 | 最近最新免费中文字幕在线| 免费看a级黄色片| 日韩大尺度精品在线看网址| 天天躁日日操中文字幕| 人人妻,人人澡人人爽秒播| 亚洲在线自拍视频| 男女视频在线观看网站免费| 最好的美女福利视频网| 午夜精品一区二区三区免费看| 夜夜爽天天搞| 午夜影院日韩av| 窝窝影院91人妻| www.www免费av| av国产免费在线观看| 亚洲中文日韩欧美视频| 久久久久九九精品影院| 午夜福利欧美成人| 国产精品不卡视频一区二区 | 91av网一区二区| 日日夜夜操网爽| 18禁裸乳无遮挡免费网站照片| 亚洲欧美日韩无卡精品| 天堂av国产一区二区熟女人妻| 一本久久中文字幕| 少妇丰满av| 好看av亚洲va欧美ⅴa在| 别揉我奶头~嗯~啊~动态视频| 免费av毛片视频| 两性午夜刺激爽爽歪歪视频在线观看| 免费观看的影片在线观看|